http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20080074925-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d829f463baf07a56b9778d3ded43b798 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 |
| filingDate | 2006-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb5c6fac6141fc26d66fd4dcf3ff19a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b789c9ee6e99f691af463ffdeee73cda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_545c4967837e53a72277d5cbf8775cf9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bbc772532db2ce3a17bf7abeb60e459 |
| publicationDate | 2008-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20080074925-A |
| titleOfInvention | Compounds for the treatment of metabolic disorders |
| abstract | Biologically active compounds of the following formula I are useful for the treatment of various metabolic disorders such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and atherosclerosis:n n n (I)n n n Wherein n is 1 or 2; one of m and x is 0 and the other is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R 2 is alkyl having 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl with 1 to 3 carbon atoms or alkoxy with 1 to 3 tango atoms; R 4 And one of R 5 is alkyl having 1 to 3 carbon atoms and the other is hydrogen or alkyl having 1 to 3 carbon atoms; A is phenyl unsubstituted or substituted by halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and 1 or 2 groups selected from perfluoromethoxy ; Or cycloalkyl having 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; Or heteroaromatic rings having 5 or 6 atoms having 1 or 2 ring heteroatoms selected from N, S, and O and such heteroaromatic rings are covalently bonded to the remainder of the compound of formula I by ring carbon; And R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. In addition, when R 1 is hydrogen, the biologically active agent may be a pharmaceutically acceptable salt of the compound of formula I. |
| priorityDate | 2005-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 284.